Low bone mineral density in hormone-naive men with prostate carcinoma

被引:0
|
作者
Smith, MR
McGovern, FJ
Fallon, MA
Schoenfeld, D
Kantoff, PW
Finkelstein, JS
机构
[1] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA
[2] Massachusetts Gen Hosp, Dept Urol, Boston, MA 02114 USA
[3] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA
[4] Dana Farber Canc Inst, Lank Ctr Genitourinary Oncol, Boston, MA 02115 USA
[5] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA
关键词
prostatic neoplasms; bone; osteoporosis; androgen-deprivation therapy;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND. The objective of this study was to determine the prevalence of low bone mineral density in men with prostate carcinoma and no history of androgen-deprivation therapy. METHODS. The authors conducted a cross-sectional study in 41 hormone-naive men with locally advanced, lymph node positive, or recurrent prostate carcinoma and no radiographic evidence of bone metastases. Bone mineral density of the total hip, posterior-anterior (PA) lumbar spine, and lateral lumbar spine was determined by dual-energy X-ray absorptiometry (DXA) using a densitometer. Trabecular bone mineral density of the lumbar spine was determined by quantitative computed tomography (QCT). Bone mineral density results were expressed in standard deviation units relative to young adult men (T score) and relative to age-matched men (Z score). RESULTS. Fourteen of 41 men [34%; 95%] confidence interval [95% CI], 20-51%) had T scores < -1.0 at one or more skeletal sites by DXA, 12 of 41 men (29%; 95% CI, 16-42%) had T scores between -1.0 and -2.5, and 12 of 41 men (5%; 95% CI, 1-17%) had T scores < -2.5. Thirty-nine of 41 men (95%; 95% CI, 83-99%) had T scores < -1.0 by QCT, 13 of 41 men (31%; 95% CI 18-48%) had T scores between -1.0 and -2.5, and 26 of 41 men (63%; 95% CI, 47-78%) had T scores < -2.5. T scores for trabecular bone mineral density of the lumbar spine were significantly lower than T scores for either the total hip (P < 0.001) or the PA lumbar spine (P ( 0.001). The mean Z score for trabecular bone mineral density of the lumbar spine was -0.7 +/- 0.9. Hypogonadism, hypovitaminosis D, and dietary calcium intakes below the Recommended Daily Allowance were observed in 20%, and 17%, and 59% of study participants, respectively. CONCLUSIONS. Many hormone-naive men with prostate carcinoma have low bone mineral density. QCT is a more sensitive method than DXA for diagnosing low bone mineral density in this patient population. Trabecular bone mineral density is lower than expected for age and risk factors for osteoporosis are common. (C) 2001 American Cancer Society.
引用
收藏
页码:2238 / 2245
页数:8
相关论文
共 50 条
  • [1] Single Infusion of Zoledronic Acid to Prevent Androgen Deprivation Therapy-induced Bone Loss in Men With Hormone-naive Prostate Carcinoma
    Satoh, Takefumi
    Kimura, Masaki
    Matsumoto, Kazumasa
    Tabata, Ken-ichi
    Okusa, Hiroshi
    Bessho, Hicleharu
    Iwamura, Masatsugu
    Ishiyama, Hiromichi
    Hayakawa, Kazushige
    Baba, Shiro
    CANCER, 2009, 115 (15) : 3468 - 3474
  • [2] Treatment of hormone-naive metastatic prostate cancer
    Hamilou, Zineb
    Saad, Fred
    Fizazi, Karim
    CURRENT OPINION IN SUPPORTIVE AND PALLIATIVE CARE, 2018, 12 (03) : 334 - 338
  • [3] Development of a Prognostic Model of Overall Survival for Metastatic Hormone-Naive Prostate Cancer in Japanese Men
    Nakagawa, Ryunosuke
    Iwamoto, Hiroaki
    Makino, Tomoyuki
    Naito, Renato
    Kadomoto, Suguru
    Akatani, Norihito
    Yaegashi, Hiroshi
    Kawaguchi, Shohei
    Nohara, Takahiro
    Shigehara, Kazuyoshi
    Izumi, Kouji
    Kadono, Yoshifumi
    Takamatsu, Atsushi
    Yoshida, Kotaro
    Mizokami, Atsushi
    CANCERS, 2022, 14 (19)
  • [4] National survey of radiation oncologists' practice patterns regarding hormone-naive prostate cancer with bone metastases
    Nakamura, Katsumasa
    Ishikawa, Hitoshi
    Akimoto, Tetsuo
    Aoki, Manabu
    Kariya, Shinji
    Kawamura, Hidemasa
    Kumano, Tomoyasu
    Kozuka, Takuyo
    Konishi, Kenta
    Sakaguchi, Masakuni
    Takayama, Kenji
    Tanaka, Osamu
    Tsuji, Hiroshi
    Hiratsuka, Junishi
    Maebayashi, Toshiya
    Mizowaki, Takashi
    Yoshioka, Yasuo
    Yorozu, Atsunori
    Tomita, Natsuo
    Ishiyama, Hiromichi
    Onishi, Hiroshi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2020, 50 (10) : 1188 - 1194
  • [5] Bone mineral density in Jamaican men on androgen deprivation therapy for prostate cancer
    Belinda F Morrison
    Ingrid E Burrowes
    William D Aiken
    Richard G Mayhew
    Horace M Fletcher
    Marvin E Reid
    Infectious Agents and Cancer, 6 (Suppl 2)
  • [6] Racial Differences in Bone Mineral Density and Fractures in Men Receiving Androgen Deprivation Therapy for Prostate Cancer
    Morgans, Alicia K.
    Hancock, Michael L.
    Barnette, K. Gary
    Steiner, Mitchell S.
    Morton, Ronald A.
    Smith, Matthew R.
    JOURNAL OF UROLOGY, 2012, 187 (03) : 889 - 893
  • [7] Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer
    Panju, Abbas H.
    Breunis, Henriette
    Cheung, Angela M.
    Leach, Marc
    Fleshner, Neil
    Warde, Padraig
    Duff-Canning, Sarah
    Krahn, Murray
    Naglie, Gary
    Tannock, Ian
    Tomlinson, George
    Alibhai, Shabbir M. H.
    BJU INTERNATIONAL, 2009, 103 (06) : 753 - 757
  • [8] Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma
    Maillefert, JF
    Sibilia, J
    Michel, F
    Saussine, C
    Javier, RM
    Tavernier, C
    JOURNAL OF UROLOGY, 1999, 161 (04) : 1219 - 1222
  • [9] The relationship between daily calcium intake and bone mineral density in men with prostate cancer
    Planas, Jacques
    Morote, Juan
    Orsola, Anna
    Salvador, Carlos
    Trilla, Enrique
    Cecchini, Lluis
    Raventos, Carles X.
    BJU INTERNATIONAL, 2007, 99 (04) : 812 - 815
  • [10] The optimal treatment of metastatic hormone-naive prostate cancer: abiraterone acetate or docetaxel?
    Aoun, Fouad
    El Rassy, Elie
    Sleilaty, Ghassan
    Assi, Tarek
    Bakouny, Ziad
    Kattan, Joseph
    FUTURE ONCOLOGY, 2017, 13 (30) : 2785 - 2790